Human small cell lung cancer cell lines (NCI-H417, NCI-H82, NCI-H2171, NCI-H847, NCI-H1048, NCI-H146, NCI-H510A, NCI-H1963, and NCI-H1876) were kindly provided by Dr. Adi Gazdar at the University of Texas Southwestern. Cells were cultured in RPMI (GE Lifesciences) supplemented with 10% heat-inactivated FBS. Cell lines were tested for and free of mycoplasma, and cell line identities were verified using short tandem repeat genotyping as compared with the original primary sample material within the CCcells database: www.CCcells.org. Small cell lung cancer cells (2 × 106 cells) were plated in 96-well plates for 24 h before treatment with inhibitors (1 nM–10 μM in 3× increment). Six replicates of each drug concentration were used. After 96 h of drug incubation, cellular viability was measured using the DIMSCAN assay, as outlined in previous studies (Kang et al., 2011 (link); Zhang et al., 2012 (link)).